孕妇接种Tdap后所产足月与早产儿接种液体六联DTaP-IPV-HB-PRP∼T疫苗基础与加强免疫的免疫原性
前瞻性观察研究纳入足月儿127例和早产儿105例,按母亲孕期是否接种Tdap分组,所有婴儿接种DTaP-IPV-HB-PRP∼T疫苗(8、12、16周基础免疫,13或15月龄加强)。基础免疫前足月儿多种抗体水平高于早产儿,母亲接种Tdap者婴儿抗体较高;免疫后各时点血清保护率和血清转化率差异小,仅基础免疫后抗-HBs≥10 mIU/mL和抗-PRP≥0.15 µg/mL足月儿高于早产儿。结论支持该疫苗在足月和早产儿中基础与加强接种。
要点
- 基础免疫前足月儿抗-D、抗脊髓灰质炎1/2/3型、抗-PT、抗-FHA和抗-PRP抗体水平高于早产儿。
- 母亲孕期接种Tdap者婴儿抗-D、抗-T、抗-PT、抗-FHA和抗-PRP抗体水平高于未接种者婴儿。
- 基础免疫后抗-HBs≥10 mIU/mL足月儿98.31% vs 早产儿89.80%,抗-PRP≥0.15 µg/mL足月儿90.91% vs 早产儿79.41%。
核心结论
- 数据支持DTaP-IPV-HB-PRP∼T疫苗用于足月和早产儿以及母亲孕期接种或未接种Tdap的婴儿的基础和加强免疫。
研究设计与样本
- 前瞻性观察研究(NCT02511327),根据分娩类型(足月或早产)和母亲孕期是否接种Tdap疫苗(Boostrix™,葛兰素史克)招募母婴,所有婴儿接种DTaP-IPV-HB-PRP∼T疫苗(Hexyon™,赛诺菲)。
- 数据合并为足月儿(N=127)和早产儿(N=105),以及母亲孕期接种Tdap者婴儿(N=199)和未接种者婴儿(N=33)。
- 所有婴儿在8、12、16周龄接受基础免疫,早产儿在13月龄、足月儿在15月龄接受加强免疫。
主要发现
- 基础免疫前,足月儿抗-D、抗脊髓灰质炎1、2、3型、抗-PT、抗-FHA和抗-PRP抗体水平高于早产儿,抗-HBs和抗-T相似。
- 基础免疫前,母亲接种Tdap者婴儿抗-D、抗-T、抗-PT、抗-FHA和抗-PRP抗体水平高于母亲未接种者婴儿,抗-HBs和抗脊髓灰质炎抗体水平两组相似。
- 基础免疫后、加强前和加强后,血清保护率(抗-D、抗-T、抗脊髓灰质炎1、2、3型、抗-HBs、抗-PRP)和血清转化率(抗-PT、抗-FHA)仅见小差异。
- 基础免疫后抗-HBs≥10 mIU/mL足月儿为98.31% vs 早产儿89.80%,抗-PRP≥0.15 µg/mL足月儿为90.91% vs 早产儿79.41%。
临床怎么用
- 原文结论支持DTaP-IPV-HB-PRP∼T疫苗用于足月和早产儿以及母亲孕期接种或未接种Tdap的婴儿的基础和加强免疫。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccination during pregnancy with tetanus, diphtheria, acellular pertussis (aP) (Tdap) antigens is important for early protection of newborn infants against pertussis, particularly for preterm infants. This study evaluated the effect of Tdap vaccination during pregnancy on the immunogenicity of a diphtheria (D), tetanus (T), aP, inactivated poliovirus (IPV), hepatitis B (HB), and Haemophilus influenzae type b (PRP ∼ T) vaccine in term and preterm populations. METHODS: A prospective, observational study (NCT02511327) recruited women and their infants based on delivery (term or preterm) and vaccination status (vaccinated with a Tdap vaccine [Boostrix™, GlaxoSmithKline] during pregnancy or not vaccinated in the last 5 years). All infants received licensed DTaP-IPV-HB-PRP ∼ T (Hexyon™, Sanofi) (8, 12, 16 week primary series and booster at 13 months of age [preterm infants] or 15 months of age [term infants]). Immunogenicity was evaluated using validated assays. Data were pooled into term (N = 127) and preterm infants (N = 105), and infants of women who received a Tdap vaccine during pregnancy (N = 199) or not (N = 33). RESULTS: Before primary vaccination, antibody levels were higher for term than preterm infants for anti-D, anti-polio 1, 2, 3, anti-PT, anti-FHA, and anti-PRP, and similar for anti-HBs and anti-T. At this time, infants of Tdap-vaccinated women had higher anti-D, anti-T, anti-PT, anti-FHA, and anti-PRP antibody levels than infants of Tdap-unvaccinated women; anti-HBs and anti-polio antibody levels were similar in both groups. Post-primary, pre-booster, and post-booster, there were only small differences in seroprotection rates (anti-D, anti-T, anti-polio 1, 2, 3, anti-HBs, anti-PRP) and seroconversion rates (anti-PT, anti-FHA), except for anti-HBs ≥ 10 mIU/mL and anti-PRP ≥ 0.15 µg/mL post-primary vaccination (higher for term [98.31 % and 90.91 %, respectively] versus preterm infants [89.80 % and 79.41 %, respectively]). CONCLUSIONS: These data support the use of DTaP-IPV-HB-PRP ∼ T vaccine for primary and booster vaccination in term and preterm born infants and in infants born to Tdap-vaccinated or Tdap-unvaccinated women.
引用
- Maertens K, Orije MRP, Huoi C, et al. Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP∼T vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy. Vaccine. 2022. PMID: 36528443. doi:10.1016/j.vaccine.2022.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。